{"product_id":"che-vrio-analysis","title":"Chemed Corporation (CHE): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Chemed Corporation (CHE) truly positioned for long-term dominance, or are its current successes built on fragile foundations? We cut straight to the core of its competitive edge by dissecting its resources through the rigorous VRIO framework - Value, Rarity, Inimitability, and Organization. Uncover the distilled summary of our findings in \u0026amp;O4\u0026amp; below, and see exactly what makes Chemed Corporation (CHE) sustainably superior (or where it needs to adapt) before you read the full analysis.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eChemed Corporation (CHE) - VRIO Analysis: 1. VITAS Market Leadership in Hospice Care\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at Chemed Corporation’s VITAS segment, and the sheer scale is the first thing that jumps out. Honestly, being the biggest player in a fragmented market like US hospice care gives them a real structural advantage, but the Medicare Cap is definitely a management headache they have to constantly juggle. Here’s the quick math on their Q3 2025 performance, which grounds this analysis.\u003c\/p\u003e\n\u003cp\u003eThe numbers from the third quarter ended September 30, 2025, show VITAS is still driving significant revenue through volume and pricing power. Their Net Patient Revenue hit \u003cstrong\u003e$407.7 million\u003c\/strong\u003e, supported by an Average Daily Census (ADC) of \u003cstrong\u003e22,327\u003c\/strong\u003e patients. To be fair, the management team is navigating some tight regulatory spots, evidenced by the \u003cstrong\u003e$6.1 million\u003c\/strong\u003e accrued in Medicare Cap billing limitation for the quarter.\u003c\/p\u003e\n\n\u003cp\u003eHere is a snapshot of the key operational metrics underpinning this market position:\u003c\/p\u003e\n\u003ctable border=\"1\"\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eMetric\u003c\/td\u003e\n    \u003ctd\u003eValue (Q3 2025)\u003c\/td\u003e\n    \u003ctd\u003eContext\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eNet Patient Revenue\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$407.7 million\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eUp 4.2% year-over-year\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eAverage Daily Census (ADC)\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e22,327\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eUp 2.5% year-over-year\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eAverage Revenue per Patient per Day\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$205.08\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eUp 298 basis points year-over-year\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eMedicare Cap Billing Limitation\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$6.1 million\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eUp from $2.2 million in Q3 2024\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eNow, let’s map this against the VRIO framework to see where the competitive edge lies. This structure helps us move past simple revenue figures to true strategic positioning.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eValue: Yes.\u003c\/strong\u003e Scale drives negotiating power and operational efficiency, evidenced by \u003cstrong\u003e$407.7 million\u003c\/strong\u003e in Q3 2025 revenue and an ADC of \u003cstrong\u003e22,327\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRarity: Yes.\u003c\/strong\u003e Being the single largest provider in the US hospice market is rare; most competitors are much smaller local or regional players.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImitability: Difficult.\u003c\/strong\u003e Replicating VITAS’s national footprint, deep regulatory expertise, and established referral pipelines requires massive, patient capital investment over many years.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOrganization: Yes.\u003c\/strong\u003e Management is organized to manage this complexity, actively optimizing patient mix and dealing with the Medicare Cap, as seen in their handling of the \u003cstrong\u003e$6.1 million\u003c\/strong\u003e limitation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe combination of unmatched scale and deep, battle-tested regulatory navigation means VITAS has a \u003cstrong\u003eSustained Competitive Advantage\u003c\/strong\u003e. What this estimate hides is the pressure from acuity mix shifts, which negatively impacted revenue growth by 121 basis points in the quarter.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eChemed Corporation (CHE) - VRIO Analysis: 2. Roto-Rooter Brand Equity and Ubiquity\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$217.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Adjusted EBITDA Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e22.7%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003e600+\u003c\/strong\u003e service locations operating throughout North America.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eFounded in \u003cstrong\u003e1935\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eCompany-owned branches\/locations: \u003cstrong\u003e116\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eIndependent contractors: Included in the \u003cstrong\u003e121\u003c\/strong\u003e company-owned branches\/independent contractors count.\u003c\/li\u003e\n\u003cli\u003eFranchisee locations: Approximately \u003cstrong\u003e337\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal system locations: More than \u003cstrong\u003e600\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eOrganization (Ubiquity)\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eU.S. Population Served: Over \u003cstrong\u003e90%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCanadian Population Served: Over \u003cstrong\u003e40%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eQ3 2025 Adjusted EBITDA Margin Decline: \u003cstrong\u003e351 basis points\u003c\/strong\u003e.\u003c\/p\u003e\n\n\n\u003cbr\u003e\u003ch2\u003eChemed Corporation (CHE) - VRIO Analysis: 3. Dual-Segment Business Diversification\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Combining the defensive, demographic-driven demand of hospice care with the non-discretionary home service needs of plumbing buffers earnings volatility.\u003c\/p\u003e\n\u003cp\u003eThe combined scale and differing growth trajectories illustrate the buffering effect:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eVITAS Healthcare\u003c\/th\u003e\n\u003cth\u003eRoto-Rooter\u003c\/th\u003e\n\u003cth\u003eConsolidated\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$407.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$217.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$624.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Growth (YoY Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e4.2%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1.1%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e3.1%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Share (2024 Est.)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e63%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e37%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e100%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderately Rare. Few companies successfully manage two such distinct, large-scale service industries.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult. It requires two completely different operational skill sets and regulatory compliance teams.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. The company successfully manages two distinct P\u0026amp;Ls, even if Roto-Rooter faced margin challenges in 2025.\u003c\/p\u003e\n\u003cp\u003eOperational metrics demonstrating the distinct nature of the segments:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eVITAS Average Daily Census (ADC) for Q3 2025 was \u003cstrong\u003e22,327\u003c\/strong\u003e, an increase of \u003cstrong\u003e2.5%\u003c\/strong\u003e year-over-year.\u003c\/li\u003e\n\u003cli\u003eVITAS Adjusted EBITDA margin (excluding Medicare Cap) for Q3 2025 was \u003cstrong\u003e17.0%\u003c\/strong\u003e, a decrease of \u003cstrong\u003e157-basis points\u003c\/strong\u003e year-over-year.\u003c\/li\u003e\n\u003cli\u003eRoto-Rooter Adjusted EBITDA margin for Q3 2025 was \u003cstrong\u003e22.7%\u003c\/strong\u003e, a decline of \u003cstrong\u003e351-basis points\u003c\/strong\u003e year-over-year.\u003c\/li\u003e\n\u003cli\u003eAs of September 30, 2025, Chemed had \u003cstrong\u003e$129.8 million\u003c\/strong\u003e in total cash and cash equivalents and \u003cstrong\u003eno\u003c\/strong\u003e current or long-term debt.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. The model provides a natural hedge against sector-specific downturns, like hospice reimbursement pressure.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eChemed Corporation (CHE) - VRIO Analysis: 4. Fortress Balance Sheet (Zero Debt)\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nZero current or long-term debt as of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e. Cash and cash equivalents totaled \u003cstrong\u003e$129.8 million\u003c\/strong\u003e as of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e. The available credit facility is \u003cstrong\u003e$550 million\u003c\/strong\u003e. Undrawn borrowing capacity was approximately \u003cstrong\u003e$404.5 million\u003c\/strong\u003e as of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric\u003c\/th\u003e\n\u003cth\u003eAmount (as of Sep 30, 2025)\u003c\/th\u003e\n\u003cth\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Debt\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCurrent and Long-Term Debt\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$129.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBalance Sheet Figure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Credit Facility\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$550 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEstablished June 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUndrawn Borrowing Capacity\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$404.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eExcluding Letters of Credit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Share Repurchases\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$180.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCash used for buybacks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRemaining Repurchase Authorization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$301.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nNo current or long-term debt reported as of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e. The total Amended and Restated Credit Agreement is \u003cstrong\u003e$550 million\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nRequires significant discipline to execute and maintain over time.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nManagement prioritized cash flow for share repurchases of \u003cstrong\u003e$180.8 million\u003c\/strong\u003e in Q3 2025. Remaining share repurchase authorization was \u003cstrong\u003e$301.8 million\u003c\/strong\u003e as of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\nShare repurchases in Q3 2025: \u003cstrong\u003e407,500\u003c\/strong\u003e shares for \u003cstrong\u003e$180.8 million\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003cli\u003e\nCost per share for Q3 2025 repurchases: \u003cstrong\u003e$443.62\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nTemporary.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eChemed Corporation (CHE) - VRIO Analysis: 5. VITAS Medicare Regulatory Acumen\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Deep, embedded knowledge of the complex Medicare reimbursement system, allowing VITAS to optimize patient mix and admissions to mitigate the Medicare Cap risk.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Yes. This specialized knowledge is concentrated and hard-won within the senior management team.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Very Difficult. It’s tacit knowledge gained from years of dealing with federal payors, not just reading a manual.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. The company actively monitors its provider numbers, with \u003cstrong\u003e24\u003c\/strong\u003e out of \u003cstrong\u003e34\u003c\/strong\u003e having a cushion of \u003cstrong\u003e10%\u003c\/strong\u003e or greater as of Q1 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. This regulatory navigation is a core, non-transferable competency in the hospice sector.\u003c\/p\u003e\n\u003cp\u003eThe following table details the Medicare Cap status for VITAS provider numbers as of the first quarter of 2025:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eCount\/Amount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Medicare Provider Numbers\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e34\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProvider Numbers with ≥10% Trailing 12-Month Cushion (Q1 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e24\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProvider Numbers with 0% to \u0026lt;10% Cushion (Q1 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProvider Numbers with Trailing 12-Month Cap Billing Limitation (Q1 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Trailing 12-Month Cap Billing Limitation (Q1 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$19.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eAdditional recent operational and financial statistics illustrating the context of this acumen include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eVITAS Net Patient Revenue for the second quarter of 2025: \u003cstrong\u003e$396.2 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eVITAS Net Patient Revenue for the first quarter of 2025: \u003cstrong\u003e$407.4 million\u003c\/strong\u003e, an increase of \u003cstrong\u003e15.1%\u003c\/strong\u003e year-over-year.\u003c\/li\u003e\n\u003cli\u003eVITAS Average Daily Census (ADC) for the first quarter of 2025: \u003cstrong\u003e22,244\u003c\/strong\u003e, an increase of \u003cstrong\u003e13.1%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eVITAS Admissions for the first quarter of 2025: \u003cstrong\u003e18,139\u003c\/strong\u003e, an increase of \u003cstrong\u003e7.3%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAverage revenue per patient per day in the second quarter of 2025: \u003cstrong\u003e$207.03\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAverage revenue per patient per day in the first quarter of 2025: \u003cstrong\u003e$207.58\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eMedicare Cap billing limitation accrued in the first quarter of 2025: \u003cstrong\u003e$2.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eProjected full-year 2025 Medicare Cap cushion status (as of Q2 2025 reporting): \u003cstrong\u003e28\u003c\/strong\u003e out of \u003cstrong\u003e35\u003c\/strong\u003e provider numbers projected to have a cushion of \u003cstrong\u003e10%\u003c\/strong\u003e or greater.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe following table presents a comparison of routine and high acuity reimbursement rates for recent periods:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eReimbursement Type\u003c\/th\u003e\n\u003cth\u003eQ1 2025 Average\u003c\/th\u003e\n\u003cth\u003eQ2 2025 Average\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoutine Home Care\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$183.06\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$183.63\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHigh Acuity Care\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1,121.07\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1,136.44\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eChemed Corporation (CHE) - VRIO Analysis: 6. Roto-Rooter’s Hybrid Service Delivery Model\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: The mix of company-owned branches and independent contractors\/franchisees allows for scalable growth while maintaining direct control over core, high-margin services.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Moderately Rare.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Moderately Difficult.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: Yes. The company uses branches for high-value add-ons (e.g., residential plumbing up \u003cstrong\u003e8.2%\u003c\/strong\u003e in Q3 2025) and contractors for broader reach.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary. While effective, the contractor revenue declined \u003cstrong\u003e4.7%\u003c\/strong\u003e in Q3 2025, showing vulnerability in that part of the model.\u003c\/p\u003e\n\u003cp\u003eRoto-Rooter Segment Financial Snapshot for Q3 2025:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eCompany-Owned Branches (Implied)\u003c\/td\u003e\n\u003ctd\u003eIndependent Contractors\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Amount\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$200.3 million\u003c\/strong\u003e (Calculated: $217.2M Total - $16.9M Contractor)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Change Y\/Y\u003c\/td\u003e\n\u003ctd\u003eImplied Growth (Total Revenue +1.1%)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-4.7%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResidential Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$150.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A (Contractor revenue not broken down)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlumbing Revenue Growth (Residential)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+8.2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eRoto-Rooter Q3 2025 Performance Metrics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal Segment Revenue: \u003cstrong\u003e$217.2 million\u003c\/strong\u003e, an increase of \u003cstrong\u003e1.1%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSegment Adjusted EBITDA: \u003cstrong\u003e$49.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSegment Adjusted EBITDA Margin: \u003cstrong\u003e22.7%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSegment Gross Margin: \u003cstrong\u003e50.7%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eChemed Total Cash and Cash Equivalents (as of September 30, 2025): \u003cstrong\u003e$129.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eChemed Corporation (CHE) - VRIO Analysis: 7. Cash Position and Shareholder Return Program\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e A cash balance of \u003cstrong\u003e$129.8 million\u003c\/strong\u003e as of September 30, 2025, combined with an active buyback program, signals management confidence. The company reported \u003cstrong\u003eno current or long-term debt\u003c\/strong\u003e as of September 30, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderately Rare. Data points illustrating capital allocation for peers are not provided, but the premise suggests a deviation from reinvesting all cash into operations.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Easy. The mechanism is a policy choice, contingent on the generation of sufficient cash flow.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. Management executed a share repurchase of \u003cstrong\u003e407,500 shares\u003c\/strong\u003e for \u003cstrong\u003e$180.8 million\u003c\/strong\u003e in Q3 2025, at a cost per share of \u003cstrong\u003e$443.62\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. This is a policy choice, not a structural advantage.\u003c\/p\u003e\n\u003cp\u003eShareholder Return Program Metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\/Value\u003c\/td\u003e\n\u003ctd\u003eDate\/Period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$129.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShare Repurchase Amount\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$180.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRemaining Repurchase Authorization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$301.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Buyback Spend Since 2011\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eOver $2.44 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSince 2011\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShares Repurchased Since 2011\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMore than 65%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSince 2011\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eDividend and Credit Facility Details:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQuarterly Cash Dividend Declared: \u003cstrong\u003e$0.60 per share\u003c\/strong\u003e, payable on August 29, 2025.\u003c\/li\u003e\n\u003cli\u003eDividend Increase: \u003cstrong\u003e20.0%\u003c\/strong\u003e increase over the \u003cstrong\u003e$0.50\u003c\/strong\u003e dividend paid in June 2025.\u003c\/li\u003e\n\u003cli\u003eConsecutive Dividends: This represents the \u003cstrong\u003e217th\u003c\/strong\u003e consecutive quarterly dividend.\u003c\/li\u003e\n\u003cli\u003eCredit Agreement Size: \u003cstrong\u003e$550 million\u003c\/strong\u003e Amended and Restated Credit Agreement entered in June 2022.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eChemed Corporation (CHE) - VRIO Analysis: 8. Strategic Acquisition Integration Capability\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The proven ability to successfully acquire and integrate hospice assets, like the Covenant Health deal for \u003cstrong\u003e$85.0 million\u003c\/strong\u003e cash, immediately boosting scale and revenue.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderately Rare. Many M\u0026amp;A deals fail to integrate smoothly; Chemed has a track record here.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult. Integration success relies on cultural alignment and operational standardization across different regulatory environments.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. The integration of Covenant Health assets contributed to Q1 2025 revenue growth of \u003cstrong\u003e$11.5 million\u003c\/strong\u003e to \u003cstrong\u003e$12.5 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. A reliable M\u0026amp;A engine is a key growth lever that few competitors execute as cleanly in this niche.\u003c\/p\u003e\n\u003cp\u003eThe successful integration of Covenant Health, closed on April 17, 2024, for \u003cstrong\u003e$85.0 million\u003c\/strong\u003e in cash, provided immediate financial uplift to the VITAS segment.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eCovenant Health Contribution (Q1 2025)\u003c\/td\u003e\n\u003ctd\u003eVITAS Segment Total (Q1 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Patient Revenue\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$11.5 million\u003c\/strong\u003e to \u003cstrong\u003e$12.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$407.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$1.8 million\u003c\/strong\u003e to \u003cstrong\u003e$2.0 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$71.8 million\u003c\/strong\u003e (Consolidated Net Income)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$2.5 million\u003c\/strong\u003e to \u003cstrong\u003e$2.7 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$70.3 million\u003c\/strong\u003e (Excluding Medicare Cap)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe operational success of the integration is evidenced by the performance metrics of the VITAS segment in Q1 2025, which also benefited from organic growth:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAverage Daily Census (ADC) growth: \u003cstrong\u003e13.1%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eAdmissions growth: \u003cstrong\u003e7.3%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eTotal VITAS ADC: \u003cstrong\u003e22,244\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eTotal VITAS Admissions: \u003cstrong\u003e18,139\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eVITAS Adjusted EBITDA Margin: \u003cstrong\u003e17.2%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eChemed's overall financial position supports continued M\u0026amp;A activity, with \u003cstrong\u003e$173.9 million\u003c\/strong\u003e in cash and \u003cstrong\u003eno debt\u003c\/strong\u003e as of March 31, 2025. During Q1 2025, the company also executed a share repurchase of \u003cstrong\u003e50,000\u003c\/strong\u003e shares for \u003cstrong\u003e$29.8 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eChemed Corporation (CHE) - VRIO Analysis: 9. High Institutional Trust and Analyst Confidence\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Very high institutional ownership at \u003cstrong\u003e95.85%\u003c\/strong\u003e suggests deep, long-term conviction from sophisticated investors, providing a stable shareholder base. The company reported Q3 2025 Adjusted EPS of \u003cstrong\u003e$5.27\u003c\/strong\u003e, missing the consensus estimate of \u003cstrong\u003e$5.39\u003c\/strong\u003e by \u003cstrong\u003e$0.12\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Yes. This level of institutional concentration is high and indicates trust in the long-term strategy.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult. It requires a long history of predictable performance and transparent reporting to earn this level of trust.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. Despite missing Q3 2025 EPS estimates, the company maintains a consensus rating of \u003cstrong\u003eModerate Buy\u003c\/strong\u003e with a \u003cstrong\u003e$574.25\u003c\/strong\u003e target. Analyst coverage shows 4 analysts with an average target of \u003cstrong\u003e$574.25\u003c\/strong\u003e, implying an upside of approximately \u003cstrong\u003e35.13%\u003c\/strong\u003e from the current price.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. This high level of trust acts as a floor during periods of short-term operational underperformance.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSupporting Financial and Statistical Data:\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional Ownership\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e95.85%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Reported Figure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnalyst Consensus Rating\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eModerate Buy\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCurrent Consensus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAverage Analyst Price Target\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$574.25\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e12-Month Target\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Reported Adjusted EPS\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.27\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Actual\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Estimated EPS\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.39\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Consensus Estimate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$624.90 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Actual\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.34 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Reported Figure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY 2025 EPS Guidance Midpoint\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$22.15\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFull Year Guidance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eAnalyst Coverage and Insider Alignment:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAnalyst consensus rating is \u003cstrong\u003eStrong Buy\u003c\/strong\u003e based on 4 analysts, with ratings including \u003cstrong\u003eBuy\u003c\/strong\u003e and \u003cstrong\u003eStrong Buy\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe lowest analyst price target is \u003cstrong\u003e$550\u003c\/strong\u003e and the highest is \u003cstrong\u003e$595\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eInsider Ownership stands at \u003cstrong\u003e3.76%\u003c\/strong\u003e as of November 28, 2025.\u003c\/li\u003e\n\u003cli\u003eThe company has been increasing its dividend for \u003cstrong\u003e16 years\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe dividend payout ratio is \u003cstrong\u003e12.69%\u003c\/strong\u003e, considered a healthy level.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516135661717,"sku":"che-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/che-vrio-analysis.png?v=1740159355","url":"https:\/\/dcf-model.com\/es\/products\/che-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}